Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on April 20, 2026 reporting Item 7.01 (Regulation FD Disclosure). New Phase 3 FoCus analyses showed greater neurologic benefit versus standard of care in Wilson disease patients with baseline neurologic symptoms.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- New Phase 3 FoCus analyses showed greater neurologic benefit versus standard of care in Wilson disease patients with baseline neurologic symptoms
- Data presented at the American Academy of Neurology Annual Meeting, April 18–22, 2026
- Positive efficacy update for ALXN1840, potentially supporting regulatory and commercial positioning in neurologic Wilson disease
- Full results and supporting data available in Exhibits 99.1 and 99.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.